Sugi Predict

Sugi Predict / Compounds / SCHEMBL1011130

SCHEMBL1011130

SCHEMBL1011130

COC(=O)c1ccc(OCCCCl)c(OC)c1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.60
▸ KMT2A Q03164 2/20 0.55
▸ CYP1A2 P05177 2/20 0.54
▸ CYP3A4 P08684 2/20 0.54
▸ CYP2C9 P11712 2/20 0.54
▸ CYP2C19 P33261 2/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.54
▸ PRSS1 P07477 4/20 0.54
▸ MGLL Q99685 1/20 0.52
▸ TSHR P16473 3/20 0.51
▸ HSP90AA1 P07900 1/20 0.51
▸ HTT P42858 1/20 0.51
▸ NPSR1 Q6W5P4 1/20 0.51
▸ MAPK1 P28482 1/20 0.50
▸ SMPD1 P17405 3/20 0.49
▸ THRA P10827 1/20 0.48
▸ THRB P10828 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4375986 0.95 MAPT (0.59) MAPTKMT2ACYP1A2CYP3A4CYP2C9
SCHEMBL1011139 0.94 MAPT (0.60) MAPTKMT2ACYP1A2CYP3A4CYP2C9
SCHEMBL1012123 0.94 MAPT (0.60) MAPTKMT2ACYP1A2CYP3A4CYP2C9
SCHEMBL2149738 0.92 MAPT (0.66) MAPTKMT2ACYP1A2CYP3A4CYP2C9
SCHEMBL5767014 0.91 MAPT (0.64) MAPTKMT2ACYP1A2CYP3A4CYP2C9
SCHEMBL5216700 0.88 MGLL (0.62) MAPTKMT2ACYP1A2CYP3A4CYP2C9
SCHEMBL15595698 0.88 MAPT (0.60) MAPTKMT2ACYP1A2CYP3A4CYP2C9
SCHEMBL1012841 0.88 MAPT (0.60) MAPTKMT2ACYP1A2CYP3A4CYP2C9
SCHEMBL6401723 0.87 HSD17B2 (0.61) MAPTKMT2ASMN1; SMN2PRSS1TSHR
SCHEMBL4376688 0.87 MAPT (0.59) MAPTKMT2ACYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114409636-B Quinazolinone compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof 沈阳药科大学 2023-04-18 — — CN claimed
CN-101792416-B Process for preparing bosutinib UNIV NANJING MEDICAL 2011-10-05 — — CN claimed
CN-101792416-A Process for preparing bosutinib UNIV NANJING MEDICAL 2010-08-04 — — CN claimed
CN-114409636-B Quinazolinone compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof 沈阳药科大学 2023-04-18 — — CN disclosed
US-11584734-B2 Tricyclic compounds as histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-02-21 — — US disclosed
EP-2956138-B1 THERAPEUTIC COMPOUNDS AND USES THEREOF KALA PHARMACEUTICALS INC (US) 2022-06-22 — — EP disclosed
CN-114409636-A Quinazolinone compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof 沈阳药科大学 2022-04-29 — — CN disclosed
US-11254651-B2 Histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2022-02-22 — — US disclosed
US-20210393641-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF OXFORD FINANCE LLC 2021-12-23 — — US disclosed
CN-106083836-B H based on quinazoline structure2S donor compound and application thereof 徐州医学院 2021-08-20 — — CN disclosed
EP-3416963-B1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2021-07-28 — — EP disclosed
WO-2000018761-A1 SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS AMERICAN CYANAMID COMPANY (US) 2000-04-06 — — WO disclosed
EP-0973746-A1 SUBSTITUTED 3-CYANO QUINOLINES American Cyanamid Company (US) 2000-01-26 — — EP disclosed
US-6002008-A Substituted 3-cyano quinolines AMERICAN CYANAMID COMPANY 1999-12-14 — — US disclosed
WO-1998043960-A1 SUBSTITUTED 3-CYANO QUINOLINES AMERICAN CYANAMID COMPANY (US) 1998-10-08 — — WO disclosed
US-5070087-A Aryl(alkyland alkylene)-N-((phenoxy and phenylthio)alkyl) aminoheterocyclics as cardiovascular, anthihistaminic, antisecretory and antiallergy agents A. H. ROBINS COMPANY, INCORPORATED (US) 1991-12-03 — — US disclosed
US-5061720-A ANTIINFLAMMATORY AGENTS FOR TOPICAL APPLICATION TO SKIN A. H. ROBINS COMPANY, INC. (US) 1991-10-29 — — US disclosed
US-4950674-A Arylalkylheterocyclic amines,N-substituted by aryloxyalkyl group in a method for allergy treatment A. H. ROBINS COMPANY, INCORPORATED (US) 1990-08-21 — — US disclosed
US-4810713-A Arylalkyl-heterocyclic amines, n-substituted by aryloxyalkyl groups used in a method for allergy treatment A. H. ROBINS COMPANY, INCORPORATED (US) 1989-03-07 — — US disclosed
EP-0235463-A2 N-substituted-arylalkyl and arylalkylene piperidines as cardiovascular antihistaminic and antisecretory agents A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) 1987-09-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210393641-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF MUC1, CFTR, SLC26A4 MAPT 1508/4885KMT2A 4807/4885CYP1A2 614/4885
US-11584734-B2 Tricyclic compounds as histone methyltransferase inhibitors EHMT1, EHMT2, BMI1 MAPT 2954/4885KMT2A 5/4885CYP1A2 4227/4885
US-11254651-B2 Histone methyltransferase inhibitors EHMT1, EHMT2, BMI1 MAPT 2463/4885KMT2A 7/4885CYP1A2 4681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.